한국인의 건강인(建康人) 및 설사환자(泄瀉患者)의 Shigella 항체가(抗體價)

하대유,정선식 대한미생물학회 1968 大韓微生物學會誌 Vol.3 No.1

Shigella antibodies in 50 sera from healthy persons and l10 sera from patients with diarrhea were tested using microdetermination of the indirect bacterial hemagglutination with the polyvalent antigen, and the following results were obtained. A survey of sera coIlected from healthy persons revealed that 4% had positive titers, 1:64 or above, to Shig. Flexneri, Shig, dysenteriae, and Shig- boydii, respectively, whereas all subjects were negative for Shig. Sonnei, less than 1:64. Namely, 6 cases among the 50 subjects were positive. Among the patients with diarrhea, positive antibody titers were demonstrated in 29. 9% agaiast Shig. fIexneri, 11. 9% against Shig. Boydii, 7.2% against Shig. Dysenteriae, and 6.4% against Shig. Sonnei, respectively. Therfoe, the total positive cases were 55.4 % among 110 subjects. No correlation between ShigelIa and Salmonella antibody titers among patients with dirrhea was fourd.

Heligmosomoides polygyrus 감염 마우스의 비장세포로 부터 만든 Conditioned Supernatant의 면역억제작용

하대유,한병갑,김명선,고유승 大韓免疫學會 1996 大韓免疫學會誌 Vol.18 No.3

Heligmosomoides polygyrus is gastrointestinal parasitic nematoda which is common parasire of wild rodents. The experimental infection with this parasite has been studied extensively in models of host-parasite interaction. The present study was undertaken to investigate both the effects of administration of conditioned supernatant or conditioned medium(CM) prepared from H. polygyrus-infected mice on the humoral and cellular immune responses in mice. Normal conditioned supernatant(NCM) was prepared from uninfected mouse splenocytes stimulated with Con A. Supematants conditioned by Con A-stimulated splenocytes of H. polygyrus -infected mice were prepared on different days post-infection, namely on day 6(HCM-D6), day 14 (HCMD14) and day 18 (HCM-D18) post-infection with H. polygyrus L3 larvae. Effects of NCM, HCM-D6, HCM-D14 and HCM-D18 on delayed-type hypersensitivity(DTH) to sheep red blood cells (SRBC), contact hypersensitivity to dinitrofluorobenzene (DNFB), hemagglutinin response to SRBC, ovalbumin (OVA)-induced active systemic anaphylaxis(ASA), and anti-OVA specific IgE were investigated. Effect of anti-IL-4 antibody (11B11) on immunoinhibitory action of HCMD18 in OVA-induced ASA was also investigated. It was found that the administration into mice of HCM-D6, HCM-D14 or HCM-D18 significantly suppressed DTH to SRBC, contact hypersensitivity to DNFB, hemagglutinin response compared with NCM. The degree of immunosuppressive activity of HCM was less marked in HCM-D6 than HCM-D14 and HCM-D18. Interestingly, HCM-D18 prepared from ICR mouse strain also showed the profound suppression of OVA-induced ASA in BALB/c and C57BL/6 mouse strains as well as in ICR mice. ASA-inhibitory activity of HCM-D18 was Somewhat abrogated in terms of mouse mortality when mice were treated in the combination of HCM-D18 and anti-IL-4 antibody, indicating that IL-4 may play a role, at least in part, in the inhibitory activity of HCM. Taken together, the present study may be the first to demonstrate that conditioned supernatants prepared from the spleen cells of H. polygyrus-infected mice may suppress the in vivo humoral and cellular immyne responses to heterologous antigens, particularly fatal anaphylaxis induced by OVA, strongly suggesting that

알코올이 Interleukin 생산, 종양발생, 감염 그리고 다른 면역반응 잠재력에 미치는 영향

하대유 주식회사 녹십자 1996 녹십자의보 Vol.24 No.1

Lymphokine을 중심으로 면역반응 조절에 대하여

하대유 주식회사 녹십자 1991 녹십자의보 Vol.19 No.5

癌患者의 腹水 및 肋膜渗出液이 健康人 淋巴球의 Rosette形成에 미치는 影響

河大有,鄭憲鐸 大韓免疫學會 1979 大韓免疫學會誌 Vol.1 No.1

Non-specific suppressions of delayed-type hypersensitivities (DTH) measured by skin reactivity to certain antigens, response of lymphocytes to mitogens and spontaneous(E) rosette formation of lymphocytes with sheep red blood cells (SRBC) have been reported to occur in cancer bearing-patients. The mechanisms responsible for these immunosuppressions remain unclear, but some investigators suggested that the immunosuppressions may result from immunosuppressive factors exudated from tumor masses. This study was undertaken to evaluate the effect of ascitic and pleural fluids from patients with cancers metastatic to peritonium or pleura. Non-cancerous ascitic and pleural effusions were used as controls. The ascitic and pleural fluids from hepatoma patients and pulmonary carcinoma patients decreased not only the percentages of early and late rosette formations severely but also the affinity of lymphocytes to SRBC. On the other hand ascitic fluids from stomach cancer patients increased the percentages of early rosette formation and the affinity of lymphocytes to SRBC. Control effusions exerted no effect on rosette formation except the pleural effusions from pulmonary tuberculosis patients. Pleural effusions obtained from tuberculosis patients slightly increased the percentages of rosette formation and the affinity of lymphocytes to SRBC.

MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease

하대유 대한면역학회 2011 Immune Network Vol.11 No.3

The great discovery of microRNAs (miRNAs) has revolutionized current cell biology and medical science. miRNAs are small conserved non-coding RNA molecules that post-transcriptionally regulate gene expression by targeting the 3’ untranslated region of specific messenger RNAs for degradation or translational repression. New members of the miRNA family are being discovered on a daily basis and emerging evidence has demonstrated that miRNAs play a major role in a wide range of developmental process including cell proliferation, cell cycle, cell differentiation, metabolism,apoptosis, developmental timing, neuronal cell fate,neuronal gene expression, brain morphogenesis, muscle differentiation and stem cell division. Moreover, a large number of studies have reported links between alterations of miRNA homeostasis and pathological conditions such as cancer, psychiatric and neurological diseases, cardiovascular disease,and autoimmune disease. Interestingly, in addition, miRNA deficiencies or excesses have been correlated with a number of clinically important diseases ranging from cancer to myocardial infarction. miRNAs can repress the gene translation of hundreds of their targets and are therefore well-positioned to target a multitude of cellular mechanisms. As a consequence of extensive participation in normal functions, it is quite logical to ask the question if abnormalities in miRNAs should have importance in human diseases. Great discoveries and rapid progress in the past few years on miRNAs provide the hope that miRNAs will in the near future have a great potential in the diagnosis and treatment of many diseases. Currently, an explosive literature has focussed on the role of miRNA in human cancer and cardiovascular disease. In this review, I briefly summarize the explosive current studies about involvement of miRNA in various human cancers and cardiovascular disease.

The Role of Regulatory T Cells in Cancer

하대유 대한면역학회 2009 Immune Network Vol.9 No.6

There has been an explosion of literature focusing on the role of regulatory T (Treg) cells in cancer immunity. It is becoming increasingly clear that Treg cells play an active and significant role in the progression of cancer, and have an important role in suppressing tumor-specific immunity. Thus, there is a clear rationale for developing clinical strategies to diminish their regulatory influences, with the ultimate goal of augmenting antitimor immunity. Therefore, manipulation of Treg cells represent new strategies for cancer treatment. In this Review, I will summarize and review the explosive recent studies demonstrating that Treg cells are increased in patients with malignancies and restoration of antitumor immunity in mice and humans by depletion or reduction of Treg cells. In addition, I will discuss both the prognostic value of Treg cells in tumor progression in tumor-bearing hosts and the rationale for strategies for therapeutic vaccination and immunotherapeutic targeting of Treg cells with drugs and microRNA. There has been an explosion of literature focusing on the role of regulatory T (Treg) cells in cancer immunity. It is becoming increasingly clear that Treg cells play an active and significant role in the progression of cancer, and have an important role in suppressing tumor-specific immunity. Thus, there is a clear rationale for developing clinical strategies to diminish their regulatory influences, with the ultimate goal of augmenting antitimor immunity. Therefore, manipulation of Treg cells represent new strategies for cancer treatment. In this Review, I will summarize and review the explosive recent studies demonstrating that Treg cells are increased in patients with malignancies and restoration of antitumor immunity in mice and humans by depletion or reduction of Treg cells. In addition, I will discuss both the prognostic value of Treg cells in tumor progression in tumor-bearing hosts and the rationale for strategies for therapeutic vaccination and immunotherapeutic targeting of Treg cells with drugs and microRNA.

Regulatory T Cell Therapy for Autoimmune Disease

하대유 대한면역학회 2008 Immune Network Vol.8 No.4

It has now been well documented in a variety of models that T regulatory T cells (Treg cells) play a pivotal role in the maintenanceof self-tolerance, T cell homeostasis, tumor, allergy, autoimmunity, allograft transplantation and control of microbial infection. Recently, Treg cell are isolated and can be expanded in vitro and in vivo, and their role is the subject of intensive investigation, particularly on the possible Treg cell therapy for various immune-mediated diseases. A growingbody of evidence has demonstrated that Treg cells can prevent or even cure a wide range of diseases, including tumor, allergic and autoimmune diseases, transplant rejection,graft-versus-host disease. Currently, a large body of data in the literature has be en emerging and provided evidence that clear understanding of Treg cell work will present definite opportunities for successful Treg cell immunotherapy for the treatment of a broad spectrum of diseases. In this Review, I briefly discuss the biology of Treg cells, and summarize effortsto exploit Treg cell therapy for autoimmune diseases. This article also explores recent observations on pharmaceutical agents that abrogate or enhance the function of Tregcells for manipulation of Treg cells for therapeutic purpose. It has now been well documented in a variety of models that T regulatory T cells (Treg cells) play a pivotal role in the maintenanceof self-tolerance, T cell homeostasis, tumor, allergy, autoimmunity, allograft transplantation and control of microbial infection. Recently, Treg cell are isolated and can be expanded in vitro and in vivo, and their role is the subject of intensive investigation, particularly on the possible Treg cell therapy for various immune-mediated diseases. A growingbody of evidence has demonstrated that Treg cells can prevent or even cure a wide range of diseases, including tumor, allergic and autoimmune diseases, transplant rejection,graft-versus-host disease. Currently, a large body of data in the literature has be en emerging and provided evidence that clear understanding of Treg cell work will present definite opportunities for successful Treg cell immunotherapy for the treatment of a broad spectrum of diseases. In this Review, I briefly discuss the biology of Treg cells, and summarize effortsto exploit Treg cell therapy for autoimmune diseases. This article also explores recent observations on pharmaceutical agents that abrogate or enhance the function of Tregcells for manipulation of Treg cells for therapeutic purpose.

Cyclosporin A 가 Polyvinylpyrroridone에 對한 마우스의 免疫反應에 미치는 影響

河大有,金哲基 대한화학요법학회 1984 대한화학요법학회지 Vol.2 No.1

Cyclosporia A(CSA)가 胸腺依存性 抗原인 緬羊赤血球와 胸腺非依存性 第2型 抗原인 polyvinylpyrroridone(PVP)에 對한 免疫反에 미치는 影響을 알아보고자 本 實驗을 實施하였다. CSA 處理는 緬羊赤血球와 PVP에 對한 plaque forming cell (PFC) 反應을 抑制하였다. 抗緬羊細胞血淸의 投與는 PVP에 對한 PFC 反應을 顯著히 亢進시켰다. 이와같은 實驗結果는 CSA가 胸腺依存性 抗原과 胸腺非依存性 第2壟 抗原에래 對한 免疫反應을 抑制하며 superessor T cell이 正常的으로 PVP에 對한 抗體反應을 抑制하고 있음을 示唆한다. This study was undertaken to assess the effect of cyclosporin A(CSA) on immune response to thymus-dependent antigen, sheep red blood cells(SRBC) and thymus independent type 2 antigen, pol~inylpSrrorjdone(P~p~. G A treatment was done by 3 subcutaneous injections. of CSA(100 mg/kg) on oae day before, at the same time of, and one day after immunization. Treatment of mice with C5A caused the profound suppression of plaque-forming cea(PFC) responses to S B C and PVP. Intravenous treatment of PW-Immunized mice with.antithjmocfie serum caused the profound enhancement of PFC response to PVP. These results indicate that CSA inhibit both thymusdependent and thymus-independent type 2 antigen and suppressor T cell3 normally function to dampen the immune response to PVP.

The Role of MicroRNAs in Regulatory T Cells and in the Immune Response

하대유 대한면역학회 2011 Immune Network Vol.11 No.1

The discovery of microRNA (miRNA) is one of the major scientific breakthroughs in recent years and has revolutionized current cell biology and medical science. miRNAs are small (19∼25nt) noncoding RNA molecules that post-transcriptionally regulate gene expression by targeting the 3’ untranslated region (3’UTR) of specific messenger RNAs (mRNAs) for degradation of translation repression. Genetic ablation of the miRNA machinery, as well as loss or degradation of certain individual miRNAs, severely compromises immune development and response, and can lead to immune disorders. Several sophisticated regulatory mechanisms are used to maintain immune homeostasis. Regulatory T (Treg)cells are essential for maintaining peripheral tolerance, preventing autoimmune diseases and limiting chronic inflammatory diseases. Recent publications have provided compelling evidence that miRNAs are highly expressed in Treg cells, that the expression of Foxp3 is controlled by miRNAs and that a range of miRNAs are involved in the regulation of immunity. A large number of studies have reported links between alterations of miRNA homeostasis and pathological conditions such as cancer, cardiovascular disease and diabetes, as well as psychiatric and neurological diseases. Although it is still unclear how miRNA controls Treg cell development and function, recent studies certainly indicate that this topic will be the subject of further research. The specific circulating miRNA species may also be useful for the diagnosis,classification, prognosis of diseases and prediction of the therapeutic response. An explosive literature has focussed on the role of miRNA. In this review, I briefly summarize the current studies about the role of miRNAs in Treg cells and in the regulation of the innate and adaptive immune response. I also review the explosive current studies about clinical application of miRNA.